AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11304721 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of diphenhydramine hydrochloride
Number of subjects: 30
Study 11304721 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 mg of naproxen sodium with 50 mg of diphenhydramine hydrochloride
Number of subjects: 30
Study 8625666 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (2 mg)
Number of subjects: 100
Study 8625666 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 1430394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 ml of MPI 5003
Number of subjects: 20
Study 1430394 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ml of MPI 5003
Number of subjects: 20
Study 6230059 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate
Number of subjects: 23
Study 6230059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 23
Study 6230059 — intervention group
Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 23
Study 3511162 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic coated incus
Number of subjects: 54
Study 3511162 — intervention group
Group type: COMPARATOR
Intervention: Uncoated incus
Number of subjects: 54
Study 30175493 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid IMT
Number of subjects: 90
Study 30175493 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic IMT
Number of subjects: 90
Study 26984210 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06439535
Number of subjects: 102
Study 26984210 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab-EU
Number of subjects: 102
Study 26984210 — intervention group
Group type: COMPARATOR
Intervention: bevacizumab-US
Number of subjects: 102
Study 25490367 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic vein exposure (EVE)
Number of subjects: 228
Study 25490367 — intervention group
Group type: COMPARATOR
Intervention: Open method of vein exposure (OVE)
Number of subjects: 228
Study 22104363 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 55
Study 22104363 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 20044537 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention
Number of subjects: 305
Study 18711764 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin (MMC) 8 mg/m(2) on day 1 and cisplatin (DDP) 25 mg/m(2) on days 1 to 3 with Kanglaite (KLT) 100 ml intravenously per day on days 1 to 14 every 3 weeks
Number of subjects: 60
Study 18711764 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin (MMC) 8 mg/m(2) on day 1 and cisplatin (DDP) 25 mg/m(2) on days 1 to 3 without Kanglaite (KLT)
Number of subjects: 60
Study 18711764 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with complete or partial responses
Number of subjects: 60
Study 18711764 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stable or progressive disease (SD or PD)
Number of subjects: 60
Study 18711764 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with clinical benefit from chemotherapy
Number of subjects: 60
Study 18711764 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stable disease of no more than 6 months or progressive disease
Number of subjects: 60
Study 15918104 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual RAAS blockade (angiotensin II receptor blocker + ACE inhibitor)
Number of subjects: 51
Study 12971702 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced upper limb rehabilitation provided jointly by a physiotherapist and occupational therapist, commencing within 10 days of stroke, available up to 30 minutes/day, five days/week for six weeks.
Number of subjects: 123
Study 12971702 — intervention group
Group type: COMPARATOR
Intervention: Control group received stroke unit care.
Number of subjects: 123
Study 12971702 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced upper limb therapy (intervention group)
Number of subjects: 123
Study 12971702 — intervention group
Group type: COMPARATOR
Intervention: Control group therapy
Number of subjects: 123
Study 12971702 — intervention group
Group type: EXPERIMENTAL
Intervention: Total amount of inpatient physiotherapy and occupational therapy received by the intervention group
Number of subjects: 123
Study 12971702 — intervention group
Group type: EXPERIMENTAL
Intervention: Service costs
Number of subjects: 123
Study 11009238 — intervention group
Group type: EXPERIMENTAL
Intervention: Plain mixture LBH (2.5 mL lidocaine 2%, 2.5 mL bupivacaine 0.5%, 5 IU/mL hyaluronidase, and 0.125 mL isotonic saline)
Number of subjects: 29
Study 11009238 — intervention group
Group type: COMPARATOR
Intervention: pH-adjusted mixture LBH-PH (2.5 mL lidocaine 2%, 2.5 mL bupivacaine 0.5%, 5 IU/mL hyaluronidase, and 0.125 mL sodium bicarbonate 8.4%)
Number of subjects: 29
Study 8769362 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) administration (0.1 IU/kg.d)
Number of subjects: 8
Study 8769362 — intervention group
Group type: EXPERIMENTAL
Intervention: T3 administration (40 micrograms on even dates or 20 micrograms on uneven dates)
Number of subjects: 8
Study 8769362 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GH and T3 administration
Number of subjects: 8
Study 8769362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1532948 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% urea ointment with 1% bifonazole (group A)
Number of subjects: 22
Study 1532948 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% urea ointment with 1% bifonazole and oral griseofulvin 500 mg/day (group B)
Number of subjects: 22
Study 1532948 — intervention group
Group type: COMPARATOR
Intervention: Oral griseofulvin alone
Number of subjects: 22
Study 3907295 — intervention group
Group type: EXPERIMENTAL
Intervention: lipid-lowering diet with cholestyramine, nicotinic acid or clofibrate
Number of subjects: 25
Study 3907295 — intervention group
Group type: COMPARATOR
Intervention: usual-care
Number of subjects: 25
Study 30794232 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported marijuana use after legalization
Number of subjects: 1000
Study 30794232 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational use reported after legalization
Number of subjects: 1000
Study 30794232 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicinal use reported after legalization
Number of subjects: 1000
Study 30794232 — intervention group
Group type: EXPERIMENTAL
Intervention: No reason for use reported after legalization
Number of subjects: 1000
Study 30794232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both recreational and medicinal use reported after legalization
Number of subjects: 1000
Study 30794232 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with marijuana use
Number of subjects: 1000
Study 29772982 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal needles
Number of subjects: 33
Study 29772982 — intervention group
Group type: COMPARATOR
Intervention: Plastic cannulae
Number of subjects: 33
Study 27089362 — intervention group
Group type: COMPARATOR
Intervention: Upright seated position (control)
Number of subjects: 8
Study 27089362 — intervention group
Group type: EXPERIMENTAL
Intervention: -20° head-down tilted position (inversion)
Number of subjects: 8
Study 25523961 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgingival mechanical therapy with azithromycin
Number of subjects: 105
Study 25523961 — intervention group
Group type: COMPARATOR
Intervention: Subgingival mechanical therapy with placebo
Number of subjects: 105
Study 25523961 — intervention group
Group type: EXPERIMENTAL
Intervention: Supragingival prophylaxis with azithromycin
Number of subjects: 105
Study 22297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control (target range 80–110 mg/dl)
Number of subjects: 63
Study 22297666 — intervention group
Group type: COMPARATOR
Intervention: Conservative glycemic control (target range 140–180 mg/dl)
Number of subjects: 63
Study 22297666 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 63
Study 20473192 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized studies
Number of subjects: 1851
Study 20473192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramic-on-polyethylene hip from one study
Number of subjects: 1851
Study 17700444 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double‐door laminoplasty (Lamino group; n = 21)
Number of subjects: 41
Study 17700444 — intervention group
Group type: COMPARATOR
Intervention: Skip laminectomy (Skip group; n = 20)
Number of subjects: 41
Study 17700444 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified double‐door laminoplasty (Lamino group)
Number of subjects: 41
Study 17700444 — intervention group
Group type: COMPARATOR
Intervention: Skip laminectomy (Skip group)
Number of subjects: 41
Study 17700444 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 15977742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive model initialization and deformation for automatic segmentation of T1-weighted brain MRI data
Number of subjects: 28
Study 12079445 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention to increase mammography rates
Number of subjects: 196
Study 12079445 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 196
Study 12079445 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 196
Study 10811588 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis with standard aspirin and beta-blockade
Number of subjects: 37069
Study 10811588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on Cox model
Number of subjects: 37069
Study 10811588 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 37069
Study 10811588 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and clinical factors
Number of subjects: 37069
Study 10811588 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 37069
Study 8979037 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional hearing aid
Number of subjects: 180
Study 8979037 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive listening device
Number of subjects: 180
Study 8979037 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both systems
Number of subjects: 180
Study 8979037 — intervention group
Group type: COMPARATOR
Intervention: No amplification condition
Number of subjects: 180
Study 1599892 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg of morphine in 0.2 ml volume mixed with 0.75% bupivacaine and 0.2 ml 1:1000 epinephrine (Group 1, n = 40)
Number of subjects: 82
Study 1599892 — intervention group
Group type: COMPARATOR
Intervention: Saline in 0.2 ml volume mixed with 0.75% bupivacaine and 0.2 ml 1:1000 epinephrine (Group 2, n = 42)
Number of subjects: 82
Study 3881447 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction with rigid internal fixation
Number of subjects: 138
Study 3881447 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment in a plaster cast
Number of subjects: 138
Study 3881447 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction with internal fixation of only the medial malleolus
Number of subjects: 138
Study 3881447 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction with rigid internal fixation according to ASIF techniques
Number of subjects: 138
Study 31085933 — intervention group
Group type: EXPERIMENTAL
Intervention: Air tamponade
Number of subjects: 34
Study 31085933 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution
Number of subjects: 34
Study 29336101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cidofovir
Number of subjects: 180
Study 29336101 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod
Number of subjects: 180
Study 28214082 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 391
Study 28214082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (6mg/h)
Number of subjects: 391
Study 28214082 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 391
Study 28214082 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (RIPC, nicorandil, control)
Number of subjects: 391
Study 26177235 — intervention group
Group type: COMPARATOR
Intervention: Real rTMS (n = 10), 1200 pulses at 1 Hz for 20 min, five daily sessions over the contralesional motor cortex.
Number of subjects: 20
Study 26177235 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n = 10), same duration and frequency as rTMS but without active stimulation.
Number of subjects: 20
Study 23405947 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss during index admission
Number of subjects: 0
Study 23405947 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in cardiac index/cardiac output
Number of subjects: 0
Study 23405947 — intervention group
Group type: COMPARATOR
Intervention: Acute heart failure (ischemic or nonischemic)
Number of subjects: 0
Study 21666990 — intervention group
Group type: EXPERIMENTAL
Intervention: hexameter recitation
Number of subjects: 17
Study 21666990 — intervention group
Group type: EXPERIMENTAL
Intervention: alliteration recitation
Number of subjects: 17
Study 21666990 — intervention group
Group type: EXPERIMENTAL
Intervention: prose verse recitation
Number of subjects: 17
Study 18645140 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib (n = 43)
Number of subjects: 85
Study 18645140 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 42)
Number of subjects: 85
Study 17305206 — intervention group
Group type: EXPERIMENTAL
Intervention: Justice-based service recovery strategies (interactional justice, distributive justice, and combination)
Number of subjects: 0
Study 17305206 — intervention group
Group type: COMPARATOR
Intervention: No service failure (control condition)
Number of subjects: 0
Study 14597909 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain polyunsaturated n-3 fatty acids
Number of subjects: 0
Study 14597909 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA; 18:3 n-3)
Number of subjects: 0
Study 14597909 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 10969367 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10969367 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microgram.kg‐1
Number of subjects: 40
Study 10969367 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 2 micrograms.kg‐1
Number of subjects: 40
Study 10969367 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 4 micrograms.kg‐1
Number of subjects: 40
Study 9286850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 50 mg
Number of subjects: 865
Study 9286850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 865
Study 9286850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 25 mg
Number of subjects: 865
Study 9286850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg
Number of subjects: 865
Study 9286850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (all doses)
Number of subjects: 865
Study 9286850 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (50 mg and 100 mg)
Number of subjects: 865
Study 9286850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study 8358913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ender nails
Number of subjects: 92
Study 8358913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sliding screw plate (SSP)
Number of subjects: 92
Study 3534592 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) for 1 year
Number of subjects: 366
Study 3534592 — intervention group
Group type: COMPARATOR
Intervention: L-PAM (melphalan) for 2 years
Number of subjects: 366
Study 29198406 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150-300mg orally per day)
Number of subjects: 28
Study 29198406 — intervention group
Group type: COMPARATOR
Intervention: Negative control (no aliskiren treatment)
Number of subjects: 28
Study 28664839 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (2 µg/day for 24 weeks)
Number of subjects: 168
Study 28664839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 25070746 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint aroma
Number of subjects: 0
Study 25070746 — intervention group
Group type: COMPARATOR
Intervention: Lavender aroma
Number of subjects: 0
Study 23511346 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized math training for 5 weeks
Number of subjects: 58
Study 23511346 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 58
Study 23511346 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized math training
Number of subjects: 58
Study 20810675 — intervention group
Group type: EXPERIMENTAL
Intervention: ASV with protocolized de-escalation (ASV-DE)
Number of subjects: 126
Study 20810675 — intervention group
Group type: COMPARATOR
Intervention: Standard ASV
Number of subjects: 126
Study 18413499 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) therapy for 4 weeks
Number of subjects: 32
Study 18413499 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (no CPAP therapy)
Number of subjects: 32
Study 16763008 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing
Number of subjects: 983
Study 16763008 — intervention group
Group type: COMPARATOR
Intervention: COC
Number of subjects: 983
Study 14634567 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted magnetic resonance imaging
Number of subjects: 17
Study 10762497 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide 600 mg daily for 5 weeks
Number of subjects: 200
Study 10762497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 10762497 — intervention group
Group type: EXPERIMENTAL
Intervention: Remacemide 150 mg or 300 mg daily for 5 weeks
Number of subjects: 200
Study 8717532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD) measurements
Number of subjects: 102
Study 8717532 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass measurements
Number of subjects: 102
Study 8717532 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass measurements
Number of subjects: 102
Study 8717532 — intervention group
Group type: EXPERIMENTAL
Intervention: BMD comparison between fractured and uninjured hip
Number of subjects: 102
Study 8717532 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative mortality and complications prediction
Number of subjects: 102
Study 8717532 — intervention group
Group type: COMPARATOR
Intervention: Comparison of survivors and non-survivors
Number of subjects: 102
Study 8717532 — intervention group
Group type: COMPARATOR
Intervention: Comparison of healed fractures and complications
Number of subjects: 102
Study 7848615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 828
Study 7848615 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 828
Study 7848615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (Women)
Number of subjects: 828
Study 7848615 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (Men)
Number of subjects: 828
Study 7848615 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (Women)
Number of subjects: 828
Study 7848615 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (Men)
Number of subjects: 828
Study 7848615 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 828
Study 2904203 — intervention group
Group type: EXPERIMENTAL
Intervention: topical timolol
Number of subjects: 12
Study 2904203 — intervention group
Group type: COMPARATOR
Intervention: betaxolol
Number of subjects: 12
Study 2904203 — intervention group
Group type: EXPERIMENTAL
Intervention: topical timolol and betaxolol
Number of subjects: 12
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (n=317)
Number of subjects: 633
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-risk group (n=317)
Number of subjects: 633
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk group (n=317)
Number of subjects: 633
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (n=316) Low-risk group
Number of subjects: 633
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (n=316) Medium-risk group
Number of subjects: 633
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation cohort (n=316) High-risk group
Number of subjects: 633
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: UNOS dataset (n=9920) Low-risk group
Number of subjects: 633
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: UNOS dataset (n=9920) Medium-risk group
Number of subjects: 633
Study 31082356 — intervention group
Group type: EXPERIMENTAL
Intervention: UNOS dataset (n=9920) High-risk group
Number of subjects: 633
Study 28470159 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's sex education program for parents (5-week, 5-session program)
Number of subjects: 58
Study 25853697 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial Coils treatment
Number of subjects: 45
Study 23552126 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor blood pressure measurement
Number of subjects: 19
Study 23552126 — intervention group
Group type: COMPARATOR
Intervention: Nurse blood pressure measurement
Number of subjects: 19
Study 21225292 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg 0.5% ropivacaine plus 25 μg fentanyl (group RF)
Number of subjects: 50
Study 21225292 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg 0.75% levobupivacaine plus 25 μg fentanyl (group LF)
Number of subjects: 50
Study 19555390 — intervention group
Group type: EXPERIMENTAL
Intervention: KM3934 (mouse-human chimeric IgG1)
Number of subjects: 0
Study 17724209 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA
Number of subjects: 15
Study 17724209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17724209 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine
Number of subjects: 15